Bone tumors are a rare and heterogeneous group of neoplasms that occur in the bone. The
diversity and considerable morphologic overlap of bone tumors with other mesenchymal …

The most frequently mutated metabolic genes in human cancer are those encoding the
enzymes isocitrate dehydrogenase 1 (IDH1) and IDH2; these mutations have so far been …

The dependency of cancer cells on glutamine may be exploited therapeutically as a new
strategy for treating cancers that lack druggable driver genes. Here we found that human …

Although molecular targeted therapies have recently displayed therapeutic effects in acute
myeloid leukemia (AML), limited response and acquired resistance remain common …

Hepatocellular carcinoma (HCC) is one of the primary liver malignancies with a poor
prognosis. Glutamic-oxaloacetic transaminase 2 (GOT2) is a highly tissue-specific gene in …

In spite of substantial progress made toward understanding cancer pathogenesis, this
disease remains one of the leading causes of mortality. Thus, there is an urgent need to …

Targeted therapies against cancer have improved both survival and quality of life of patients.
However, metabolic rewiring evokes cellular mechanisms that reduce therapeutic …

Background Alterations in metabolism are one of the emerging hallmarks of cancer cells and
targeting dysregulated cancer metabolism provides a new approach to developing more …

Simple Summary Chondrosarcomas are cartilage tumours that often harbour a mutation in
one of the isocitrate dehydrogenase (IDH) genes. IDH mutations are important drivers at the …

Despite advancements in cancer management, tumor relapse and metastasis are
associated with poor outcomes in many cancers. Over the past decade, oncogene-driven …